Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

BACKGROUND: First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Stenehjem, David D., Hahn, Andrew W., Gill, David M., Albertson, Daniel, Gowrishankar, Banumathy, Merriman, Joseph, Agarwal, Archana M., Thodima, Venkata, Harrington, Erik B., Au, Trang H., Maughan, Benjamin L., Houldsworth, Jane, Pal, Sumanta K., Agarwal, Neeraj
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6347137/
https://ncbi.nlm.nih.gov/pubmed/30682039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0210415
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars